Skip to Content
MilliporeSigma
All Photos(2)

Key Documents

SML3477

Sigma-Aldrich

RO5166017

≥95% (HPLC)

Synonym(s):

(4S)-2-Amino-N-ethyl-4,5-dihydro-N-phenyl-4-oxazolemethanamine, (S)-4-((Ethyl(phenyl)amino)methyl)-4,5-dihydrooxazol-2-amine

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C12H17N3O
CAS Number:
Molecular Weight:
219.28
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Orally active, high-affinity, potent and selective trace amine-associated receptor 1 (TAAR1) agonist with antipsychotic-like efficacy in vivo.

RO5166017 is an orally active, high-affinity, potent and selective trace amine-associated receptor 1 (TAAR1) agonist (mouse/rat/human/monkey Ki = 1.9/2.7/31/24 nM, cAMP EC50 = 3.3/14/55/97 nM using respective HEK293 transfectants; GIRK EC50 = 8 nM with mTAAR1-expressing Xenopus oocytes; neurons firing frequency IC50 = 1.73/2.99 nM in mouse VTA/DRN slices) with good selectivity over TAAR4 and 123 other proteins. RO5166017 reduces spontaneous hyperlocomotion in Dat-/- mice (0.5 mg/kg ip.), as well as hyperlocomotion induction by cocaine or NMDAR agonist L-687,414 in wild-type (0.01-0.3 mg/kg po.), but not Taar1-knockout mice.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Role of trace amine-associated receptor 1 in nicotine's behavioral and neurochemical effects
Neuropsychopharmacology, 43(12), 2435-2444 (2018)
TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity
Proceedings of the National Academy of Sciences of the USA, 108(20), 8485-8490 (2011)
F G Revel et al.
Molecular psychiatry, 18(5), 543-556 (2012-05-30)
Schizophrenia is a chronic, severe and highly complex mental illness. Current treatments manage the positive symptoms, yet have minimal effects on the negative and cognitive symptoms, two prominent features of the disease with critical impact on the long-term morbidity. In

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service